Medtronic Cardio/Neuro Buys Stimulate Wall Street In 1998 - Stock Up 42%
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's tried and true ability to post solid operating results while simultaneously revamping its product profile to meet shifting market demands provided Wall Street with a dual reason to reward the firm's share price in 1998. The company's stock gained 41.5%, or 21-3/4 points, to close the year at 74-9/32.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.